| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -2.0 | -1.4 |
| EPS (diluted, $ a share) | $-0.59 | $-0.48 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NYSE: KAPA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Kairos Pharma, LTD.: key numbers
- Share price
- $0.4069Close, Nov 16
- Market cap
- $1.91M
- Shares outstanding
- 4.69MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Kairos Pharma, LTD.
All →Kairos Pharma Capital Raise
Kairos Pharma, Ltd. entered into a third amendment to its existing equity line of credit (ELOC) purchase agreement with Helena Global Investment Opportunities I Ltd. The amendment extends the company's option to use the ELOC for an additional year until December 31, 2028, and follows previous amendments that adjusted the purchase price to 97% of VWAP and shortened the pricing period.
- Counterparty
- Helena Global Investment Opportunities I Ltd.
- Term
- through Dec 2028
Kairos Pharma Clinical Trial Data
Kairos Pharma reported positive interim efficacy data from its Phase 2 trial of ENV-105 (carotuximab) in combination with apalutamide for metastatic castration-resistant prostate cancer. The combination therapy demonstrated a statistically significant median progression-free survival of 17.7 months compared to 2 months for apalutamide alone (P=0.0008). Based on these results, the company has modified the trial protocol to enroll patients earlier in the disease progression and targets trial completion by Q4 2027.
Kairos Pharma Investor Presentation
Kairos Pharma, Ltd. issued a new investor presentation to be presented by CEO John Yu at the H.C. Wainwright 28th Annual Global Investment Conference in New York. The presentation provides an update on the company's clinical programs and activities.
- Counterparty
- H.C. Wainwright 28th Annual Global Investment Conference